Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 119 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/9/2009 First Published: 11/1/2001


1.		Phase III Randomized Study of Erlotinib in Patients With Incurable Stage IIIB or IV Non-Small Cell Lung Cancer Refractory to Standard Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CAN-NCIC-BR21 OSI-CAN-NCIC-BR21, NCT00026325, BR21

Last Modified: 6/15/2007 First Published: 11/1/2001


2.		Phase III Randomized Study of Gemcitabine With or Without Erlotinib in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CAN-NCIC-PA3 OSI-CAN-NCIC-PA3, NCT00026338, PA3

Last Modified: 12/6/2007 First Published: 1/1/2002


3.		Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Erlotinib (Tarceva) in Patients With Chemotherapy Naive Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GENENTECH-OSI2298g MSKCC-01122, NCT00029016


4.		A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				OSI3199g NCT00091663


5.		A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				OSI3364g NCT00130728

Last Modified: 2/25/2008 First Published: 12/2/2005


6.		Phase III Randomized Study of Maintenance Therapy Comprising Erlotinib Versus Observation in Patients With High-Risk Stage I or Stage II-IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Previously Treated With First-Line, Platinum-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Other				EORTC-55041 EUDRACT-2004-004333-34, NCT00263822


7.		A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				AVF3671g NCT00257608

Last Modified: 6/8/2007 First Published: 8/6/2006


8.		Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				NCI				NCCTG-N05C4 N05C4, NCCTG N05C4, NCT00362986


9.		Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				D4200C00057 EUDRACT No. 2006-000259-16, NCT00364351


10.		A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				Pharmaceutical / Industry				BO18192 NCT00556712

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute